Barnett International Announces Investor Relations Conference for Biotech and Life Science Companies.

Business Editors & Health/Medical Writers

BIOWIRE2K

SAN DIEGO--(BUSINESS WIRE)--Oct. 16, 2002

Conference Provides Investor Relations Strategies for Today's Tough

Market Environment

Barnett International announces its upcoming conference, Strategic Investor Relations: Advanced IR Strategies for both Private and Public Biotech and Life Science Companies, to be held Nov. 21-22, 2002 at the Manchester Grand Hyatt in San Diego.

A PDF copy of the conference brochure is available for download at http://www.barnettinternational.com/pdfs/BI-929EM1.pdf

Conference sessions provide IR strategies for today's tough market, including: managing expectations after "the bubble," employing innovative investor outreach, as well as strategies for regaining the attention and trust of Wall Street. Inclusive in the conference is an interactive investor panel discussion as well as a workshop on crafting corporate positioning and building an effective corporate presentation.

The conference will feature a speaking faculty of industry leaders composed of investors, in-house IR professionals and industry specialists. Speakers include representatives from Applied Molecular Evolution, Affymetrix, Inhale Therapeutic Systems, Tularik, ZymoGenetics, Alliance Pharmaceutical Corp., Genome Therapeutics, MacDougall Biocommunications, Atkins & Associates, CCBN, Commcore Communications, Weisscom Partners and Kureczka/Martin Associates.

Barnett International provides consulting services, conferences and training programs for the biotechnology, pharmaceutical and life sciences markets. For further information about this conference and other Barnett services, visit the Web site at www.barnettinternational.com or contact Barnett International directly at 610/565-2622.

Barnett International is a division of PAREXEL International Corp., one of the largest biopharmaceutical outsourcing organizations in the world, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. With a commitment to providing solutions that expedite time-to-market and peak market penetration, PAREXEL has developed significant expertise in clinical trials management, data management, biostatistical analysis, medical marketing, clinical pharmacology, regulatory and medical consulting, industry training and publishing and other drug development consulting services.

Its newest subsidiary, Perceptive Informatics Inc., provides a variety of technology products and services, including Web-based portal solutions and voice and data systems, which are designed to accelerate and enhance the clinical development and launch processes. The Company's integrated services, therapeutic area depth and sophisticated information technology, along with its experience in global drug development and product launch services, represent key competitive strengths. Headquartered near Boston, PAREXEL operates in 55 locations throughout 36 countries around the world, and has approximately 4,660 employees.

This release contains "forward-looking" statements regarding future results and events, including statements regarding expected financial results, future growth and customer demand that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements.

Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects" and similar expressions are intended to identify forward-looking statements. The company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the cancellation, revision, or delay of contracts, including those contracts in backlog; the company's dependence on certain industries and clients; the company's ability to win new business, manage growth, and attract and retain employees; the company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; government regulation of certain industries and clients; competition and consolidation within the pharmaceutical industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations.

Such factors and others are discussed more fully in the section entitled "Risk Factors" of the company's Form 10-Q for the period ended Dec. 31, 2001, as filed with the Securities and Exchange Commission, which "Risk Factors" discussion is incorporated by reference in this press release. The company disclaims any duty to update any of the forward-looking statements contained in this press release.